➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Merck
Johnson and Johnson
Baxter
Express Scripts

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,637,553

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,637,553 protect, and when does it expire?

Patent 8,637,553 protects STIVARGA and is included in one NDA.

This patent has sixty-five patent family members in thirty-nine countries.

Summary for Patent: 8,637,553
Title:Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Abstract: A compound of Formula (I): ##STR00001## salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.
Inventor(s): Boyer; Stephen (Hilden, DE), Dumas; Jacques (Bethany, CT), Riedl; Bernd (Wuppertal, DE), Wilhelm; Scott (Orange, CT)
Assignee: Bayer Healthcare LLC (Tarrytown, NY)
Application Number:10/895,985
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,637,553
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 8,637,553

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.